Table 2. Joint-effects survival analysis of SLC family genes expression levels with OS in patients.
| Group | SLC19A3 | SLC25A39 | SLC39A11 | Patients | Number of events | MST | Crude HR (95% CI) | Crude P value | Adjusted HR (95% CI) | Adjusted P valuea |
|---|---|---|---|---|---|---|---|---|---|---|
| A | Low | High | – | 24 | 15 | 501 | 1 | 1 | ||
| B | Low | Low | – | 32 | 24 | 407 | 1.272 (0.664–2.435) | 0.469 | 1.229 (0.541–2.796) | 0.622 |
| C | High | Low | – | 32 | 15 | 883 | 3.533 (1.730–7.215) | 0.001 | 4.598 (1.948–10.851) | <0.001 |
| D | High | High | – | 24 | 15 | 592 | 1.549 (0.786–3.055) | 0.206 | 1.797 (0.782–3.682) | 0.181 |
| I | Low | – | High | 25 | 17 | 521 | 1 | 1 | ||
| II | Low | – | Low | 31 | 22 | 373 | 0.531 (0.275–1.025) | 0.057 | 0.511 (0.232–1.129) | 0.097 |
| III | High | – | Low | 31 | 15 | 826 | 2.221 (1.063–4.639) | 0.034 | 3.294 (1.265–8.574) | 0.015 |
| IV | High | – | High | 25 | 15 | 652 | 1.269 (0.611–2.635) | 0.523 | 1.216 (0.530–2.791) | 0.645 |
| 1 | – | Low | Low | 42 | 21 | 773 | 1 | 1 | ||
| 2 | – | Low | High | 14 | 9 | 630 | 0.671 (0.303–1.484) | 0.324 | 0.705 (0.273–1.819) | 0.47 |
| 3 | – | High | Low | 14 | 11 | 506 | 0.546 (0.257–1.159) | 0.115 | 0.495 (0.215–1.139) | 0.098 |
| 4 | – | High | High | 42 | 28 | 509 | 0.442 (0.245–0.797) | 0.007 | 0.448 (0.225–0.891) | 0.022 |
Italic P values indicate statistically significant. a, adjusted for histologic grade, radiation therapy, radical resection, and targeted molecular therapy. SLC, solute carrier; MST, median survival time; OS, overall survival; PDAC, pancreatic ductal adenocarcinoma; HR, hazard ratio; CI, confidence interval.